European Pharmaceutical Review
JULY 4, 2022
Ensuring potential microbial contaminants are not transferred into cleanroom environments is a key aspect of risk mitigation strategies. In a review, pharmaceutical microbiologist and contamination control expert Tim Sandle, reviewed several methods of material transfer, listing the decontamination methods based on efficacy and commenting on their weaknesses. .
pharmaphorum
JULY 4, 2022
GSK’s recently-unveiled plan to develop a bioscience cluster close to its main R&D site in Stevenage, UK, has moved closer to fruition, now that the first partners have joined the initiative. The asset management arm of Swiss back UBS has formed a joint venture with property developer Reef Group that will develop the 33-acre campus in Stevenage, Hertfordshire.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JULY 4, 2022
Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. Following the option exercise, Vir will receive the option exercise fee, regulatory and commercial milestone payments as well as tiered royalties on net product sales from Brii Bio.
pharmaphorum
JULY 4, 2022
Today’s rare disease landscape comprises of around 7,000 different diseases. With a broad and diverse range of symptoms and severities impacting patients around the world, connecting these individuals with the information and expertise needed to achieve the correct diagnosis can be extremely lengthy and pose a significant barrier to treatment. “As the severity, progress, and treatment potential of rare diseases varies from patient to patient, each condition is going to need to be addressed diffe
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
European Pharmaceutical Review
JULY 4, 2022
Lonza announced that it is investing approximately CHF 500 million (€500m) to build a new flexible fill and finish facility in Stein, Switzerland. The facility will be located on the same campus as Lonza’s clinical drug product facility, allowing the company to leverage existing infrastructure, capabilities and talent. . According to the company, the investment completes the company’s strategic commitment to offer an integrated end-to-end service that includes commercial drug product manufacturi
pharmaphorum
JULY 4, 2022
David Weingard, chief impact officer of T1D Moonshot and founder of Cecelia Health, tells us how T1D Moonshot aims to break silos and advance type 1 diabetes prevention and treatment options by utilising numerous partners’ expertise. In the US alone, 37.3 million Americans live with diabetes, with 1.6 million having type 1 diabetes (T1D). Still, a scarcity of T1D treatments exists.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
pharmaphorum
JULY 4, 2022
Two weeks after reporting disappointing results for its lead coeliac disease therapy, 9 Meters Biopharma will draw some comfort from a mid-stage trial of its candidate for short bowel syndrome (SBS), although its share price remains under pressure. Interim results of the VIBRANT study of vurolenatide have identified a suitable dosing regimen for the drug to take forward into phase 3, with preliminary evidence of efficacy and a favourable safety profile, said the North Carolina biotech. 9 Meters
Pharma Times
JULY 4, 2022
The development is part of company’s mission to support patient access to clinical trials
pharmaphorum
JULY 4, 2022
Two years into the COVID-19 pandemic, engaging with healthcare professionals about treatments has never been more difficult. Consultants, doctors, and nurses are overworked, stressed, and tired. Backlogs in hospitals show no sign of clearing. The old multichannel approach to medical and commercial strategy is no longer as effective as it once was. Simply blitzing doctors and consultants with as much information as possible fails to drive engagement when many healthcare professionals struggle to
Pharma Times
JULY 4, 2022
The deal will give Advanz an increased presence in the treatment of rare diseases
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmaceutical Technology
JULY 4, 2022
The US’s pharma industry registered a 3.0% drop in IT hiring activity in June 2022 when compared with the previous month, according to GlobalData’s Job Analytics database. The industry’s overall hiring is decreased by 5.96% in June 2022 when compared with May 2022. Out of the pharma industry’s total hiring activity, IT jobs claimed a 1.92% share in June 2022, recording an increase of 0.05% over the last three-month average share.
pharmaphorum
JULY 4, 2022
Teva chief executive Kare Schultz has lined up the appointment he wants to revitalise the company’s R&D operations, naming Vertex Pharma’s Eric Hughes to the role of executive vice president of R&D and chief medical officer. Eric A Hughes. Hughes – currently Vertex’s head of clinical development and translational medicine – will make the move to his new employer on 1 August, less than a year after taking on the role.
Pharmaceutical Technology
JULY 4, 2022
UK-based company AstraZeneca’s IT hiring declined 12.3% in June 2022 when compared with the previous month, according to GlobalData’s Job Analytics database. The company’s overall hiring activity declined by 9.51% in June 2022 when compared with May 2022. IT jobs claimed an 8.11% share in the company’s total hiring activity in June 2022, and recorded a 0.16% growth over the last three-month average share.
pharmaphorum
JULY 4, 2022
The UK government has made an additional £175 million ($212 million) in funding available for its push to make the country a go-to location for clinical research, adding to £200 million promised in March to strengthen the national data infrastructure. The new money has been announced to coincide with the publication of a new three-year strategic plan aimed at recovering the UK’s capacity to deliver research following the pandemic, increasing national capacity for clinical research, and imp
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmaceutical Technology
JULY 4, 2022
Germany-based company Bayer’s IT hiring declined 8.0% in June 2022 when compared with the previous month, according to GlobalData’s Job Analytics database. The company’s overall hiring activity declined by 10.56% in June 2022 when compared with May 2022. IT jobs claimed a 6.24% share in the company’s total hiring activity in June 2022, and recorded a 0.43% growth over the last three-month average share.
Pharmaceutical Technology
JULY 4, 2022
US-based company Johnson & Johnson’s IT hiring rose 57.2% in June 2022 when compared with the previous month, according to GlobalData’s Job Analytics database. The company’s overall hiring activity increased by 46.7% in June 2022 when compared with May 2022. IT jobs claimed a 4.3% share in the company’s total hiring activity in June 2022, and recorded a 0.49% growth over the last three-month average share.
Pharmaceutical Technology
JULY 4, 2022
Switzerland-based company F. Hoffmann-La Roche’s IT hiring declined 16.3% in June 2022 when compared with the previous month, according to GlobalData’s Job Analytics database. The company’s overall hiring activity declined by 11.52% in June 2022 when compared with May 2022. IT jobs claimed an 8.21% share in the company’s total hiring activity in June 2022, and recorded a 1.41% decline over the last three-month average share.
Pharmaceutical Technology
JULY 4, 2022
US-based company MerckInc’s IT hiring declined 1.2% in June 2022 when compared with the previous month, according to GlobalData’s Job Analytics database. The company’s overall hiring activity declined by 13.1% in June 2022 when compared with May 2022. IT jobs claimed a 5.91% share in the company’s total hiring activity in June 2022, and recorded a 0.71% growth over the last three-month average share.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmaceutical Technology
JULY 4, 2022
The proportion of pharmaceutical companies hiring for cloud related positions rose in June 2022 compared with the equivalent month last year, with 44.8% of the companies included in our analysis recruiting for at least one such position. This latest figure was higher than the 40.2% of companies who were hiring for cloud related jobs a year ago but a decrease compared to the figure of 47.1% in May 2022.
Pharmaceutical Technology
JULY 4, 2022
Spain’s pharma industry registered a 25.5% drop in IT hiring activity in June 2022 when compared with the previous month, according to GlobalData’s Job Analytics database. The industry’s overall hiring is decreased by 7.41% in June 2022 when compared with May 2022. Out of the pharma industry’s total hiring activity, IT jobs claimed a 7.72% share in June 2022, recording a decrease of 3.34% over the last three-month average share.
Pharmaceutical Technology
JULY 4, 2022
The UK’s pharma industry registered a 4.9% drop in IT hiring activity in June 2022 when compared with the previous month, according to GlobalData’s Job Analytics database. The industry’s overall hiring is decreased by 3.02% in June 2022 when compared with May 2022. Out of the pharma industry’s total hiring activity, IT jobs claimed a 3.85% share in June 2022, recording a decrease of 0.22% over the last three-month average share.
Pharmaceutical Technology
JULY 4, 2022
GlaxoSmithKline (GSK) has completed the acquisition of all outstanding shares of US-based Sierra Oncology in a deal totalling $1.9bn (£1.6bn), in cash. In April this year, GSK entered an agreement for the acquisition of Sierra Oncology for $55 per share. The conclusion of the deal comes after the shareholders of Sierra Oncology approved the takeover on 29 June this year.
Pharmaceutical Technology
JULY 4, 2022
Russia is an already insular country and its worldview has tended to be self-contained, but this has hardened in the face of recent sanctions and counter-sanctions imposed during the war with Ukraine. Compared with other emerging pharmaceutical markets (such as India and China, covered in previous Emerging Market Outsourcing Reports), Russian facilities lack many US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals, meaning Russian manufacturing is more focused on
Expert insights. Personalized for you.
134 
Let's personalize your content